This confirms the similar observations of giving CY before immunotherapy to achieve better antitumor or immunostimulating efficacy (23), whereas CY given at the time of immunotherapy with systemic IL-2 led to enhanced tumor growth rather than tumor inhibition (24). This evidence concerns the gene IL2 and neoplasm.